Company intelligence / Profile preview

Createrna

Wuhan, Hubei, China

Ownership: Private
Employees: ~240
Development stage: Other

Overview

Numerous small molecule candidates across immunology, cardiovascular, nephrology, and respiratory disease areas; most advanced programs are in Phase 2, focusing on targets such as IRAK4 for psoriasis and AT2R for heart failure, with robust preclinical to Phase 1-2 activity in related indications[4].

Therapeutic areas: DermatologyImmunologyGastroenterologyPulmonologyNephrologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

None publicly disclosed as major pharmaceutical partners (Vivo Capital is a key investor)

Beyond the preview

Go deeper on Createrna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Createrna.

Explore the full profile